The effect of variable domain orientation and arrangement on the antigen-binding activity of a recombinant human bispecific diabody

Cao, 1998, Bispecific antibodies as novel bioconjugates, Bioconjug. Chem., 9, 635, 10.1021/bc980044l van Spriel, 2000, Immunotherapeutic perspective for bispecific antibodies, Immunol. Today, 21, 391, 10.1016/S0167-5699(00)01659-5 Segal, 2001, Introduction: bispecific antibodies, J. Immunol. Methods, 248, 1, 10.1016/S0022-1759(00)00338-0 Lu, 1999, Acquired antagonistic activity of a bispecific diabody directed against two different epitopes on vascular endothelial growth factor receptor 2, J. Immunol. Methods, 230, 159, 10.1016/S0022-1759(99)00135-0 Lu, 2001, Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor, Cancer Res., 61, 7002 Lu, 2004, Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody, J. Biol. Chem., 279, 2856, 10.1074/jbc.M310132200 Carter, 1995, Toward the production of bispecific antibody fragments for clinical applications, J. Hematother., 4, 463, 10.1089/scd.1.1995.4.463 Plückthun, 1997, New protein engineering approaches to multivalent and bispecific antibody fragments, Immunotechnology, 3, 83, 10.1016/S1380-2933(97)00067-5 Todorovska, 2001, Design and application of diabodies, triabodies, and tetrabodies for cancer targeting, J. Immunol. Methods, 248, 47, 10.1016/S0022-1759(00)00342-2 Carter, 2001, Bispecific human IgG by design, J. Immunol. Methods, 248, 7, 10.1016/S0022-1759(00)00339-2 Holliger, 1993, “Diabodies”: small bivalent and bispecific antibody fragments, Proc. Natl. Acad. Sci. USA, 90, 6444, 10.1073/pnas.90.14.6444 Whitlow, 1994, Multivalent Fvs: Characterization of single-chain Fv oligomers and preparation of a bispecific Fv, Protein Eng., 7, 1017, 10.1093/protein/7.8.1017 Zhu, 1996, High level secretion of a humanized bispecific diabody from Escherichia coli, Bio/technology (NY), 14, 192, 10.1038/nbt0296-192 Xiong, 2002, Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20×anti-CD3 bispecific diabody, Cancer Lett., 177, 29, 10.1016/S0304-3835(01)00758-3 Gao, 2004, Efficient inhibition of multidrug-resistant human tumors with a recombinant bispecific anti-P-glycoprotein×anti-CD3 diabody, Leukemia, 18, 513, 10.1038/sj.leu.2403267 De Haard, 1999, A large non-immunized human Fab fragment phage library that permit rapid isolation and kinetic analysis of high affinity antibodies, J. Biol. Chem., 274, 18218, 10.1074/jbc.274.26.18218 Burtrum, 2003, A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo, Cancer Res., 63, 8912 Zhu, 1998, Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library, Cancer Res., 58, 3209 Perisic, 1994, Crystal structure of a diabody, a bivalent antibody fragment, Structure, 2, 1217, 10.1016/S0969-2126(94)00123-5 Carmichael, 2003, The crystal structure of an anti-CEA scFv diabody assembled from T84.66 scFvs in V(L)-to-V(H) orientation: implications for diabody flexibility, J. Mol. Biol., 326, 341, 10.1016/S0022-2836(02)01428-6 Kipriyanov, 2003, Effect of domain order on the activity of bacterially produced bispecific single-chain Fv antibodies, J. Mol. Biol., 330, 99, 10.1016/S0022-2836(03)00526-6 Lu, 2003, Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity, J. Biol. Chem., 278, 43496, 10.1074/jbc.M307742200